glp 1/gip agonist Frontiers Science Behind GLP 1 GIP
Description
The results of a trial of semaglutide in obese patients with HFpEF showed a significant amelioration of symptoms and improvements in motor function and weight loss compared with patients treated with a placebo
TripleHormone-Receptor Agonist Retatrutide for Obesity a Phase 2 Trial
10.1016/j.ejphar.2024.176905 126 YinW.JiangY.XuS.WangZ.PengL.FangQ.et al (2019)
Cell Biosci
In order to be able to address these, businesses will need to understand: What GLP-1RAs are, how they are used and how they are likely to evolve going forward
